Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pudafensine - Initiator Pharma

Next Previous
Drug Profile

Pudafensine - Initiator Pharma

Alternative Names: IP-2015; IP-2017; IPNP-2015; IPTN-2021

Latest Information Update: 29 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Initiator Pharma
  • Developer Initiator Pharma; MAC Clinical Research; National Institute of Drug Abuse
  • Class Analgesics; Drug withdrawal therapies; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Neurotransmitter uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Erectile dysfunction
  • Phase I Neuropathic pain; Trigeminal neuralgia; Vulvodynia
  • Preclinical Female sexual dysfunction; Pain; Substance-related disorders

Most Recent Events

  • 29 Jul 2025 Phase-I clinical trials in Vulvodynia (unspecified route) prior to July 2025 (Initiator pharma pipeline, July 2025)
  • 29 Jul 2025 Preclinical trials in Female sexual dysfunction in Denmark (unspecified route)
  • 29 Jul 2025 Initiator pharma plans a phase IIa trial forVulvodynia (Initiator pharma pipeline, July 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top